A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort.

doi:10.1182/blood.2024025834

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort.

Blood - 28 Nov 2024

Goldfinger Mendel, Mantzaris Ioannis, Shastri Aditi, Saunthararajah Yogen, Gritsman Kira, Sica R Alejandro, Kornblum Noah, Shah Nishi, Levitz David, Rockwell Bradley, Shapiro Lauren C, Gupta Ridhi, Pradhan Kith, Xue Xiaonan, Munoz Anne, Dhawan Aradhika, Fehn Karen, Comas Monica, Verceles Jhannine Alyssa, Jonas Brian A, Kambhampati Suman, Shi Yang, Braunschweig Ira, Cooper Dennis L, Konopleva Marina, Feldman Eric J, Verma Amit

Abstract excerpt

ABSTRACT: A metronomic, low-dose schedule of decitabine and venetoclax was safe and effective in myeloid malignancies with few dose reductions or interruptions in an older diverse population. Median overall survival for patients with acute myeloid leukemia and a TP53-mutation was 16.1 and 11.3 months, respectively. This trial was registered at www.clinicaltrials.gov as #NCT05184842.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Azacitidine

Share to Bridged Bicyclo Compounds, Heterocyclic

Share to Decitabine

Share to Drug Administration Schedule

Share to Leukemia, Myeloid, Acute

Share to Sulfonamides

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 39316768
DOI: 10.1182/blood.2024025834
PMCID: PMC11619782

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A weekly low-dose regimen of decitabine and venetoclax is efficacious and less myelotoxic in a racially diverse cohort.PMID 39316768Read ↗

Outcomes of TP53‐mutant acute myeloid leukemia with decitabine and venetoclaxSemantic proximity Read ↗

Oral decitabine and cedazuridine plus venetoclax for older or unfit patients with acute myeloid leukaemia: a phase 2 studySemantic proximity Read ↗

TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes.Semantic proximity Read ↗

Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial.Semantic proximity Read ↗

TP53 Mutations and Circulating Blasts ≥ 20% Are the Primary Determinants of Survival in Accelerated/Blast-Phase Myeloproliferative Neoplasms Treated With Frontline Venetoclax Plus Hypomethylating Agent.Semantic proximity Read ↗

Outcomes in Patients with Poor-Risk Cytogenetics with or without TP53 Mutations Treated with Venetoclax and Azacitidine.Semantic proximity Read ↗

A phase 3b study of venetoclax and azacitidine or decitabine in an outpatient setting in patients with acute myeloid leukemiaSemantic proximity Read ↗

Venetoclax and hypomethylating agents in TP53‐mutated acute myeloid leukaemiaSemantic proximity Read ↗

Decitabine with etoposide is effective in TP53 mutated myeloid tumors via overcoming differentiation blockSemantic proximity Read ↗

The history of oral decitabine/cedazuridine and its potential role in acute myeloid leukemiaSemantic proximity Read ↗

Comparing venetoclax in combination with hypomethylating agents to hypomethylating agent-based therapies for treatment naive TP53-mutated acute myeloid leukemia: results from the Consortium on Myeloid Malignancies and Neoplastic Diseases (COMMAND)Semantic proximity Read ↗

Mutational landscape and response are conserved in peripheral blood of AML and MDS patients during decitabine therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.